Development of a BNP1-32 Immunoassay That Does Not Cross-React with proBNP

Lewis, Lynley K.; Raudsepp, Sara D; Yandle, Tim G.; Prickett, Timothy C. R.; Richards, A. Mark

doi:10.1373/clinchem.2016.269712

Cited by 22 publications

(23 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results reported by Lewis et al [53] confirmed that on average, the BNP 1-32 concentration in healthy subjects is very low (median under 1 ng/L). The setup of a new generation of commercial BNP immunoassay methods with a relevant increment in both analytical sensitivity and specificity is needed in order to detect these very low analyte concentrations.…”

Section: Hf Therapy With Arni: Is It the Time For The Renaissance Of mentioning

confidence: 60%

“…As expected, this new ELISA for BNP 1-32 measured much lower BNP values than the commercial BNP method using the fully automated ARCHITECT platform. In 22 healthy subjects, the median (interquartile range) BNP concentration measured by the specific ELISA was 0.29 (0.2-0.6) ng/L, whereas the median value measured by ARCHITECT method was 17.3 (8.7-22.5) ng/L; even larger was the difference in BNP values measured by these two methods in a group of HF patients: 40.7 (2.0-90.1) ng/L (n = 42) vs. 1778 (1134-2853) ng/L (n = 39), respectively [53]. Interestingly, despite greatly lower values measured, this ELISA for BNP showed a percent increase in median BNP concentrations from the groups of healthy controls to HF patients slightly higher than that of ARCHITECT method (59% vs. 44%).…”

Section: Quality Specifications For An Accurate Bnp Assaymentioning

confidence: 82%

“…Fortunately, a very recent study [53] may offer a solution to this clinically relevant analytical problem. For the first time, Lewis et al [53] were able to set up an ELISA method that measures BNP in plasma without interference by proBNP.…”

Section: Quality Specifications For An Accurate Bnp Assaymentioning

confidence: 99%

“…For the first time, Lewis et al [53] were able to set up an ELISA method that measures BNP in plasma without interference by proBNP. This two-site ELISA uses a specific polyclonal antibody that recognizes the amino-terminal end of BNP 1-32 and does not cross-react with proBNP, in conjunction with a C-terminal antibody, which recognizes BNP [26][27][28][29][30][31][32] .…”

Section: Quality Specifications For An Accurate Bnp Assaymentioning

confidence: 99%

“…At this point, it is important to discuss whether a more sensitive and specific BNP assay, as that described by Lewis et al [53], could add further and/or more accurate information on pathophysiological and clinical conditions of HF patients under LCZ696 treatment. As a matter of fact, proBNP cross-reacts by about 14%-17% with BNP in the ADVIA BNP assay [36,56], which is the laboratory method used in the PARADIGM-HF trial for BNP assay [9].…”

Section: Hf Therapy With Arni: Is It the Time For The Renaissance Of mentioning

confidence: 99%

See 4 more Smart Citations

New issues on measurement of B-type natriuretic peptides

Clerico

Zaninotto

Passino

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Abstract:The measurement of the active hormone of B-type natriuretic peptide (BNP) system actually has several analytical limitations and difficulties in clinical interpretations compared to that of inactive peptide N-terminal proBNP (NT-proBNP) because of the different biochemical and pathophysiological characteristics of two peptides and quality specifications of commercial immunoassay methods used for their measurement. Because of the better analytical characteristics of NT-proBNP immunoassays and the easier pathophysiological and clinical interpretations of variations of NT-proBNP levels in patients with heart failure (HF), some authors claimed to measure the inactive peptide NT-proBNP instead of the active hormone BNP for management of HF patients. The measurement of the active peptide hormone BNP gives different, but complementary, pathophysiological and clinical information compared to inactive NT-proBNP. In particular, the setup of new more sensitive and specific assays for the biologically active peptide BNP 1-32 should give better accurate information on circulating natriuretic activity. In conclusion, at present time, clinicians should accurately consider both the clinical setting of patients and the analytical characteristics of BNP and NT-proBNP immunoassays in order to correctly interpret the variations of natriuretic peptides measured by commercially available laboratory methods, especially in patients treated with the new drug class of angiotensin receptor-neprilysin inhibitors.

show abstract

Section: Hf Therapy With Arni: Is It the Time For The Renaissance Of mentioning

confidence: 60%

Section: Quality Specifications For An Accurate Bnp Assaymentioning

confidence: 82%

Section: Quality Specifications For An Accurate Bnp Assaymentioning

confidence: 99%

Section: Quality Specifications For An Accurate Bnp Assaymentioning

confidence: 99%

Section: Hf Therapy With Arni: Is It the Time For The Renaissance Of mentioning

confidence: 99%

See 3 more Smart Citations

New issues on measurement of B-type natriuretic peptides

Clerico

Zaninotto

Passino

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

How does neprilysin inhibition in heart failure work?

Richards

Pemberton

Yandle

2019

European J of Heart Fail

View full text Add to dashboard Cite

This article refers to 'Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study' by H. Nougué et al., published in this issue on pages 598-605.A compellingly positive, large randomized controlled therapeutic trial, augmented by many ancillary studies and sub-analyses, indicates therapy based on combined angiotensin II type 1 receptor blockade and neprilysin inhibition (ARNI) confers an approximate 20% benefit for all major clinical endpoints in chronic heart failure (HF) compared to treatment based on angiotensin-converting enzyme inhibition (ACEI). 1 Patients across a broad range of age, co-morbidities and concurrent treatments enjoy net benefit from ARNI over periods of at least 1-2 years, which seemingly constitutes the greatest advance in the pharmacotherapy of HF made in the last 25 years. The treatment has received full endorsement from authoritative international clinical guidelines and will eventually be prescribed to millions of patients worldwide in expectation of major benefit. 2,3 Neprilysin cleaves cardiac natriuretic peptides and it is generally assumed augmentation of intact bioactive natriuretic peptides in plasma and tissues underlies the beneficial effects of neprilysin inhibition (NEPi). It is important we understand the mechanisms underpinning the biological effects of ARNI in order to anticipate both advantageous and adverse effects and to potentially improve on the current ARNI options and garner further benefits from later drug modifications. The B-type cardiac peptides, B-type natriuretic peptide (BNP) and N-terminal pro BNP (NT-proBNP), are the best known natriuretic peptides in the clinical community having had long-term exposure as well-established diagnostic and prognostic biomarkers and as therapy in the form of human recombinant BNP (nesiritide). Subsequently BNP has been invoked as mediating important effects in ARNI and early neurohormonal sub-studies in ARNI therapy have focused upon these peptides. 4 However, as emphasized by Nougué et al. 5 in the current issue of the Journal, BNP is not the key natriuretic peptide affected by, or mediating the effects of, NEPi and natriuretic peptides are not the sole set of potentially important neprilysin substrates involved.The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology.Nougué et al. 5 studied 73 patients with chronic HF undergoing conversion from ACEI-based to ARNI-based treatment with sacubitril/valsartan. Reduction in New York Heart Association class and improved echocardiographic findings observed over 90 days reflected clinical benefit from the new treatment. A dose-dependent fall in plasma neprilysin activity was associated with increased plasma concentrations of substance P, atrial natriuretic peptide (ANP), and glucagon-like peptide-1 (GLP-1) and decreased fructosamine. Soluble ST2 and cardiac troponin also fell. Whilst ANP r...

show abstract

Detection of B-type natriuretic peptide by establishing a low-cost and replicable fluorescence resonance energy transfer platform

Shang

et al. 2020

Microchim Acta

View full text Add to dashboard Cite

Development of a BNP1-32 Immunoassay That Does Not Cross-React with proBNP

Abstract: We have developed the first assay that measures BNP1-32 in plasma without interference by proBNP. Analysis of larger patient cohorts is now required to compare the performance of this assay with current less specific assays for the diagnosis or prognosis of HF.

Cited by 22 publications

References 37 publications

New issues on measurement of B-type natriuretic peptides

New issues on measurement of B-type natriuretic peptides

How does neprilysin inhibition in heart failure work?

Detection of B-type natriuretic peptide by establishing a low-cost and replicable fluorescence resonance energy transfer platform

Contact Info

Product

Resources

About